Drugs / AP203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05473156 | Jul 2023 → Dec 2026 expected | esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma | AP Biosciences Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05473156 ↗ |
| Route | Intravenous | “Participants will be administered by intravenous (IV) infusion” NCT05473156 ↗ |